Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

40.0%

2 terminated out of 5 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

5Total
P 1 (5)

Trial Status

Recruiting3
Terminated2

Clinical Trials (5)

Showing 5 of 5 trials
NCT06586957Phase 1Recruiting

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

NCT05735080Phase 1Recruiting

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

NCT05252416Phase 1Terminated

(VELA) Study of BLU-222 in Advanced Solid Tumors

NCT05867251Phase 1Recruiting

Study of AVZO-021 in Patients With Advanced Solid Tumors

NCT06264921Phase 1Terminated

A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors

Showing all 5 trials

Research Network

Activity Timeline